Aug. 9, 2013
/PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO
is scheduled to present at the Canaccord Genuity 2013 Annual Growth Conference at
3:00 p.m. EDT
Wednesday, August 14
, 2013. The conference is being held
at the The InterContinental Boston.
A live webcast of the Company's presentation at the conference will be available via a link provided at
. A replay of the webcast will be available for 90 days at the site after the presentation.
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare
Ventricular Assist System features the HVAD
pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in
the United States
for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 35 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at
HeartWare International, Inc. is a member of the Russell 2000 ® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.